Tuesday, 18 Dec 2018

You are here

Predicting Autoimmune Progression in ANA+ Patients

Positive tests results for antinuclear antibodies (ANAs) are frequently referred to rheumatology despite their poor predictive value, even in individuals who are ‘At Risk’ for autoimmune connective tissue diseases (AI-CTDs). A new study shows that combining ANA positive with interferon-stimulated gene expression increased the liklihood of progression to AI-CTD.

This prospective observational study studied 118 individuals who were ANA positive, had one or more SLE criteria for <12 months and were treatment-naïve. They also used 49 healthy controls (HCs) and 114 SLE were used as negative and positive controls. 

Over a 12-month period, 19/118 (16%) progressed to AI-CTD (SLE=14, primary Sjogren’s=5).

Baseline IFN (IFN-A, IFN-B) scores differed among At-Risk, HCs and SLE groups (p<0.001) and were elevated in At-Risk who progressed to AI-CTD at 12 months.

Those who progressed to AI-CTD did not have other distinguishing baseline clinical characteristics or ultrasound findings.

The odds of progression were more likely in those with a family history of autoimmune rheumatic disease  (OR 8.2 (95% CI 1.58 to 42.53) and IFN-Score-B (OR 3.79;1.50–9.58).

While gene testing for IFN signatures would be interesting, if not advantageous, the question remains whether this would be cost effective and predictive in individuals without a positive family history and without lupus-specific clinical characteristics.  Nonethless, this approach allows for the potential of early stratification of individuals At-Risk for AI-CTD.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Genetic Diagnosis for Previously Undiagnosed Disorders

The NEJM has reported the NIH's Undiagnosed Diseases Network (UDN) study results of genetically identifying new diseases from prospectively followed persons with undiagnosed disorders. The UDN was formed in 2014 as a network of seven clinical sites, two sequencing cores, a coordinating center, central biorepository, a metabolomics core, and a model organisms screening center. It was established to apply a multidisciplinary model in the evaluation of the most challenging cases and to identify the biologic characteristics of newly discovered diseases.

SLE and Risk of Malignancy

The risk for cancer in systemic lupus erythematosus (SLE) patients has been inconsistently studied.  A new metanalysis shows that SLE has an increased risk for 16 specific cancers and decreased risk for prostate cancer and cutaneous melanoma. 

The Benefits of a Lupus Clinic

A comparative cohort study assessing the quality of care in patients with systemic lupus erythematosus (SLE) suggests that a dedicated lupus clinic has better quality measure performance compared to lupus management in a general rheumatology clinic.

A study from Rush University enrolled 150 consecutive SLE patients - with 73 followed in the general rheumatology clinic and 77 followed in a dedicated lupus clinic. 

Diagnosing Early Lupus from Mimics

A multicenter study of early systemic lupus erythematosus (SLE) patients examined manifestations at disease onset and found that certain clinical features can help to distinguish early SLE from other SLE‐mimicking conditions. 

High CV Risk in Lupus

Patients with systemic lupus erythematosus (SLE) remain at risk for accelerated atherosclerosis, and important questions have yet to be answered, British investigators reported.